Prognostic Value of [ 18 F]FDG PET Combined with [ 68 Ga]Ga-PSMA PET as Pretreatment Imaging in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with [ 177 Lu]Lu-PSMA-617
Journal of Nuclear Medicine · 2026-11 · 67 (11) · 1797-1803
DOI: 10.2967/jnumed.126.273113 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 13.08.2026. Verfasst von Adam Bekkhoucha und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, CHRU Nancy, Nancyclotep Imaging Platform, Nancy, France. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Heterocyclic Compounds, 1-Ring, Prostatic Neoplasms, Castration-Resistant, Dipeptides. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy with [177Lu]Lu-PSMA-617 has reshaped the management of metastatic castration-resistant prostate cancer (mCRPC). This study aimed to assess the added prognostic value of [18F]FDG PET beyond [68Ga]Ga-PSMA-11 PET as pretreatment imaging and to develop an overall survival (OS) nomogram for patients with mCRPC who were treated with [177Lu]Lu-PSMA-617.
Methods
From February 2022 to November 2023, all patients with mCRPC treated with at least 1 cycle of [177Lu]Lu-PSMA-617 were analyzed. Baseline [68Ga]Ga-PSMA-11 and [18F]FDG PET parameters (SUVmax, SUVmean, total metabolic tumor volume [TMTV], and total lesion activity) were extracted for both tracers. OS was modeled using 2 hierarchical least absolute shrinkage and selection operator Cox models: clinical covariates plus [68Ga]Ga-PSMA-11 PET (M-PSMA) and clinical covariates plus [68Ga]Ga-PSMA-11 PET plus [18F]FDG PET (M-PSMA + FDG). Model discrimination was assessed using the optimism-corrected Harrell concordance index (C-index), whereas model improvement was assessed with changes in the C-index.
Results
The study included 99 patients with mCRPC, and the median OS was 14 mo (95% CI, 11.7-18.2 mo). In M-PSMA, the [68Ga]Ga-PSMA-11 PET SUVmean was the only significant imaging parameter (hazard ratio, 0.897; 95% CI, 0.852-0.945; P < 0.001). The addition of TMTV [18F]FDG PET in M-PSMA + FDG yielded a modest improvement in prognostic performance (ΔC-index, 0.010; 95% CI, -0.021 to 0.044) but a refined risk prediction for patients with a high TMTV [18F]FDG burden. The final model was used to construct a nomogram for predicting 12-mo OS probability.
Conclusion
Quantitative [68Ga]Ga-PSMA-11 PET parameters provide strong prognostic stratification in patients with mCRPC who were treated with [177Lu]Lu-PSMA-617. Tumor burden, as measured on [18F]FDG PET, adds incremental prognostic information beyond [68Ga]Ga-PSMA-11 PET, resulting in a modest improvement in risk prediction and potential refinement of prognosis in selected high-risk patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, CHRU Nancy, Nancyclotep Imaging Platform, Nancy, France.
- CHRU Nancy, INSERM, Université de Lorraine, CIC 1433, Innovation Technologique, Nancy, France.
- IADI, INSERM U1254, Université de Lorraine, Nancy, France; and.
- Department of Endocrinology, CHRU Nancy, Nancy, France.
- Department of Nuclear Medicine, CHRU Nancy, Nancyclotep Imaging Platform, Nancy, France; c.boursier@chru-nancy.fr.
Zitieren
APA
Bekkhoucha, A., Zaragori, T., Olivier, P., Claudin, M., Marie, P. Y., Kunsch, J., Verger, A., Raymond, P., Heyer, S., Imbert, L., & Boursier, C. (2026). Prognostic Value of [ 18 F]FDG PET Combined with [ 68 Ga]Ga-PSMA PET as Pretreatment Imaging in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with [ 177 Lu]Lu-PSMA-617. Journal of Nuclear Medicine, 67(11), 1797-1803. https://doi.org/10.2967/jnumed.126.273113
Vancouver
Bekkhoucha A, Zaragori T, Olivier P, Claudin M, Marie PY, Kunsch J, et al. Prognostic Value of [ 18 F]FDG PET Combined with [ 68 Ga]Ga-PSMA PET as Pretreatment Imaging in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with [ 177 Lu]Lu-PSMA-617. Journal of Nuclear Medicine. 2026;67(11):1797-1803. doi:10.2967/jnumed.126.273113
BibTeX
@article{Bekkhoucha2026,
author = {Bekkhoucha, Adam and Zaragori, Timothée and Olivier, Pierre and Claudin, Marine and Marie, Pierre-Yves and Kunsch, Julien and Verger, Antoine and Raymond, Perrine and Heyer, Sébastien and Imbert, Laetitia and Boursier, Caroline},
title = {Prognostic Value of [ 18 F]FDG PET Combined with [ 68 Ga]Ga-PSMA PET as Pretreatment Imaging in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with [ 177 Lu]Lu-PSMA-617},
journal = {Journal of Nuclear Medicine},
year = {2026},
volume = {67},
number = {11},
pages = {1797--1803},
doi = {10.2967/jnumed.126.273113}
}
EUVIMED